ERBB3 and neoplasm: However, the ERBB2-targeting antibodies trastuzumab and pertuzumab block the formation of signaling-competent ERBB3/ERBB2 heterodimers, and this mechanism has been shown to be critical for the anti-tumor effect [14, 16, 17].